Amylyx Pharmaceuticals
NEWS
Here’s who rang in the New Year by joining the NASDAQ or raising private equity funds.
A member of BioSpace’s Class of 2021, CODA aims to modify neuronal cell populations using gene therapy to express a tunable ligand-gated ion channel.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
QurAlis’ first piece of the puzzle is a protein called stathmin-2, which is encoded by the STMN2 gene.
Amylyx’s decision to submit the NDA, announced Wednesday morning, came on the heels of recent discussions with the FDA, including a pre-NDA meeting held on July 15.
The panels discussed key issues such as expanded access programs (EAPs), clinical trial diversity, conditional approval pathways, and patient experience data.
The Boston-based company announced an infusion of $135 million in Series C funds to support the late-stage development of its lead candidate, AMX0035, for amyotrophic lateral sclerosis.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Besides providing a sense of hope for children with this devastating disease, this research could offer another clue toward unlocking the mystery behind other forms of ALS.
JOBS
IN THE PRESS